基于《中国医疗机构药品评价与遴选快速指南》(第二版)的rhGH量化评价

Quantitative Evaluation of Recombinant Human Growth Hormone (rhGH) Based on the Quick Guide for Drug Evaluation and Selection in Chinese Medical Institutions (Second Edition)

关键词:  重组人生长激素  药品评价  遴选指南  药学特性  有效性  安全性  经济性

Key words:  Srecombinant human growth hormone (rhGH)  drug evaluation  selection guideline  pharmaceutical properties  efficacy  safety  economic attributes

摘要:

目的：对人生长激素制剂进行综合临床评价，为医疗机构药品遴选和临床合理用药提供参考依据。方法：基于《中国医疗机构药品评价与遴选快速指南》（第二版）评价体系，从药学特性、有效性、安全性、经济性和其他属性五个维度对生长激素进行量化评分，并依据评分结果划分推荐级别。结果：原研药诺泽和长效制剂金赛增评分分别为74.9和71.2，为强推荐；赛增水针、粉针和珍怡水针、粉针以及安苏萌粉针、水针评分分别为66.8、63.3和61.5、61.5以及61.4、60.2，均为弱推荐。结论：原研和长效生长激素的综合评分高，但其价格也较高，建议通过医保谈判纳入医保目录、参与国家集采等方式降低价格，提高可及性。

Abstract:

Objective: To conduct a comprehensive clinical evaluation of human growth hormone preparations, providing evidence for the selection of medications in medical institutions and supporting rational clinical use.Methods: Based on the evaluation framework of the Quick Guide to Drug Evaluation and Selection in Chinese Medical Institutions (2nd Edition), growth hormone products were quantitatively assessed across five dimensions: pharmaceutical properties, efficacy, safety, economy, and other attributes. Recommendation levels were determined according to the total scores.Results: The original drug Norditropin and the long-acting formulation Jintropin AQ scored 74.9 and 71.2 respectively, receiving a strong recommendation; while Saizen liquid, powder, Genheal liquid, powder, and Ansomone powder, liquid scored 66.8, 63.3, 61.5, 61.5, and 61.4, 60.2 respectively, all receiving a weak recommendation.Conclusion: The original and long-acting growth hormones have high comprehensive scores, but their prices are also relatively high. It is recommended to reduce prices and improve accessibility through methods such as including them in the medical insurance catalog via medical insurance negotiations and participating in national centralized drug procurement.